Precision oncology has traditionally focused on matching single drugs to single molecular alterations. However, most advanced cancers harbour multiple actionable pathways, raising the question of whether multi-drug regimens tailored to individual tumour DNA profiles could deliver better outcomes than conventional sequencing approaches.
A new study published in the Journal of Clinical Oncology reports that patients treated with personalised combination therapies based on tumour genomic profiling experienced improved clinical outcomes compared with standard treatment strategies, providing early clinical evidence for a more nuanced approach to molecularly guided care.
Researchers analysed outcomes in patients with advanced solid tumours who received individualised multi-drug regimens selected according to tumour DNA sequencing results, targeting more than one oncogenic pathway simultaneously. Treatment selection was informed by genomic alterations identified on next-generation sequencing and matched to available targeted or pathway-directed therapies.
CLINICAL SUMMARY
What was examined
Clinical outcomes associated with personalised multi-drug treatment strategies guided by tumour DNA sequencing in patients with advanced solid tumours.
Key findings
-
Genomically guided combination regimens were associated with improved response and disease control compared with standard approaches.
-
Benefits were observed across tumour types, including cancers with complex molecular profiles.
-
Combination treatment was deliverable with acceptable toxicity in selected patients.
Clinical implications
-
Precision oncology may increasingly require multi-target strategies rather than single-agent matching.
-
Broader molecular profiling may improve treatment individualisation in advanced disease.
-
Multidisciplinary interpretation of tumour genomics will be critical to safely implement this approach.
In this first global tumour DNA-guided multi-drug therapy trial, patients experienced enhanced clinical benefit compared with conventional approaches, with improved response and disease control reported across several tumour types, including cancers with historically limited targeted options.
HER2 Uncovered: From Low to Ultralow – Get the Low Down with Ben Dessauvagie & Gelareh Farshid
Importantly, toxicity was manageable, and dose adjustments allowed many patients to remain on combination treatment long enough to derive benefit, suggesting that multi-agent precision strategies can be delivered safely in selected patients.
These findings challenge the traditional one-mutation-one-drug paradigm and support a shift toward systems-oriented precision oncology, where multiple tumour vulnerabilities are addressed concurrently. This approach may be particularly relevant for patients with heavily pre-treated or molecularly complex disease.
The results also strengthen arguments for broad molecular profiling and integrated molecular tumour boards, as treatment decisions become increasingly dependent on interpreting multiple genomic signals rather than a single driver alteration.
Paper: Sicklick JK, et al. Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations. J Clin Oncol. 2026 Jan 8:JCO2501453. doi: 10.1200/JCO-25-01453. Epub ahead of print. PMID: 41505666. Access online here.
